Cellexus Limited Announces New Directors to Enhance its’ Management Team
News Dec 09, 2013
Cellexus Limited has appointed Mr Stephen Lee as its’ new Executive Technical Director and Dr Linda Cammish as a new Non-Executive Director to enhance the Cellexus Management Team and Board of Directors as the Company expands.
Mr Lee is a Fellow of the Institute of Mechanical Engineers with over 40 years manufacturing management experience. His early career was at Pfizer R&D developing a range of new medical devices.
He was responsible for developing a number of pharmaceutical products at Bioprogress and managed the edible film manufacturing plant at BioTec Films LLC. He has been a Board member of a number of companies and is trustee of a pension fund.
Dr Cammish brings additional sales, marketing and business development experience to the Cellexus Board. With over 29 years experience in the life science area she has considerable expertise in growing businesses in this sector.
With extensive practical experience in senior leadership, business development, sales and marketing roles in companies including Millipore, PerSeptive Biosystems, Applied Biosystems and Abcam, she also has Board level experience and was more recently CEO at nanoTherics.
Mr Bob Cumming, Cellexus Limited General Manager, said in a statement, "Mr Lee has an excellent all round knowledge of engineering and its’ application to solving real problems in science and engineering and we are delighted that he is bringing this to Cellexus to further develop the Cellexus CellMaker range of single-use bioreactor products.”
He added, “Having achieved some significant milestones in product development and design to improve the flexibility of the CellMaker systems we are now in a phase of focussed commercialization of these new products so the addition of Dr Cammish to our Board of Directors, bringing a huge level of commercial experience in this sector to our Board team, is very timely. We are delighted to welcome both Mr Lee and Dr Cammish to their new roles to facilitate driving the Company forward through our next stage of growth.
Mr Lee added: "The Cellexus CellMaker products have been developed with next-generation technology and I am delighted to join the team to help further extend the product range and manage the production of the highly robust CellMaker systems to meet customers’ needs.”
Dr Cammish commented: “I am very pleased to be appointed as NED of the Cellexus Board. I look forward to working with the Directors and Management to drive growth through further sales of the Company’s proprietary single use disposable bioreactor products and the new products the Company will be launching.”
The Cellexus CellMaker range of automated systems apply a next-generation technology of single-use, disposable cell culture bioreactor bags which have highly efficient methods to mix and oxygenate. Whilst other systems require shakers, rockers, rollers or large environmental chambers, the CellMaker systems employ a novel airlift technology which is simple, scalable, inexpensive to use and proven to provide highly efficient cell culture to out-perform cell culture in flasks.
The CellMaker Bags, which are the unique single-use, disposable cell culture bags in which cells are grown in the CellMaker systems, enable fast set-up times, eliminate cleaning requirements and prevent cross-contamination.
The CellMaker systems very efficiently aerate the CellMaker Bags with controlled air flow providing oxygen for highly efficient cell growth with gentle and effective mixing to maintain cells in suspension.
Pressure control enhances oxygen availability to cells and decreases foaming whilst temperature control enables production of high yields of soluble protein under the most optimal conditions.
Molecular Key for Delaying Multiple Sclerosis ProgressionNews
In work just published it was possible to identify a receptor known as P2X4 present in the microglial cells that increases their anti-inflammatory potential in order to reduce the damage in Multiple Sclerosis and, above all, encourage the body's own repair responses.READ MORE
T Cells Attack and Kill Dopamine-Producing Cells in Parkinson's diseaseNews
Researchers in Germany discover a potential new target for treating Parkinson's diseaseREAD MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE